Sangamo Therapeutics

Phase A — Understand the business

Lens 1 · Company Overview

Sangamo Therapeutics is a clinical-stage genomic-medicine company and one of the field's founding names — it pioneered zinc-finger protein engineering (zinc-finger nucleases / ZFNs for editing, and zinc-finger transcriptional regulators / ZF-TRs for gene regulation) starting in the 1990s. It has no approved products and no product revenue; its income is entirely collaboration and license/royalty revenue from partners using its platforms.

The business has three asset layers:

1. Delivery platform (the crown jewel): the STAC-BBB AAV capsid — engineered to cross the blood-brain barrier after IV dosing, with claimed "industry-leading brain tropism," ~700-fold higher transgene expression than benchmark AAV9 in non-human primates. Plus the SIFTER capsid-engineering platform and a modular integrase (MINT) platform.
2. Clinical assets: isaralgagene civaparvovec (ST-920) for Fabry disease (lead, rolling BLA underway); giroctocogene fitelparvovec for hemophilia A (Phase 3-positive, returned by Pfizer); ST-503 for chronic neuropathic pain (early clinical).
3. Preclinical / strategic focus: "core neurology" — prion disease (ST-506) and tauopathies, delivered via STAC-BBB + ZF-TR cargo.

Customers/partners (these are the revenue): Genentech (Roche), Astellas Gene Therapies, and Eli Lilly hold STAC-BBB/epigenetic-regulation license deals; Pfizer (terminated, eff. Apr 2025); plus non-therapeutic royalty licensees Sigma-Aldrich and Ligand (ex-Open Monoclonal Technology). Contract structure is the classic biotech out-license: modest upfronts + target-add fees + downstream milestones + royalties — i.e. mostly contingent and partner-controlled. The customers.csv on the shelf is empty, so the partner roster here is filing-derived.

Plain-terms verdict: a deep-IP platform company that never converted a single asset into an approved, revenue-generating product before running out of money. HQ Richmond, CA; incorporated Delaware; CEO Sandy Macrae since June 2016.

Lens 2 · Supply Chain

For a pre-revenue gene-therapy company the "supply chain" is R&D inputs → manufacturing → the regulator → the partner/payer rather than a goods chain. The shelf's supply-chain.md is missing, so this is filing + web derived.

• Upstream inputs: plasmid DNA, AAV viral-vector production (cell culture + purification), zinc-finger / integrase protein engineering, and CDMO manufacturing capacity. Sangamo states STAC-BBB is "manufacturable at commercial scale using standard cell culture and purification processes" — a key selling point to the bidders.
• The company: historically ran its own manufacturing (Brisbane, CA; Valbonne/France cell-therapy site; UK subsidiary). It has been dismantling that footprint — France wind-down + Valbonne closure (2024 France Restructuring), Brisbane closure underway, $13.2M impairment on the Brisbane right-of-use asset in 2025. Now operates from Richmond, CA.
• The gatekeeper: the FDA is the binding node — the BLA for ST-920 is mid-rolling-submission, and the company itself flags FDA staffing/policy disruption as a risk.
• Downstream "buyers": the pharma partners (Genentech/Astellas/Lilly) who would carry programs through late-stage development and global commercialization; ultimately payers/health systems for any approved gene therapy.

Chokepoints / single-source dependencies: (1) capital is the true single-source dependency — the company has no internal cash engine and depends entirely on partners + equity raises; (2) the partners themselves — losing one (Pfizer) cascaded into the crisis; (3) AAV manufacturing yield/cost, the perennial gene-therapy bottleneck that has crushed the economics of approved one-time therapies industry-wide (cf. the durability/cost doubts that led Pfizer to drop near-approval hemophilia gene therapy).

Lens 3 · Competitive Advantages (moats)

What's genuinely defensible:

• IP estate — multiple patent families on capsid technologies (STAC-BBB, STAC-102, STAC-103) with expected expirations 2040–2045, plus a patent on a candidate cellular receptor for STAC-BBB (exp. ~2045). Two decades of zinc-finger and capsid IP is the asset Lilly is paying for.
• STAC-BBB performance — if the NHP data translate, a CNS-penetrant capsid is the single most valuable enabling tool in neuro gene therapy (Alzheimer's, Parkinson's, ALS, Huntington's, prion, tau). The fact that three large partners (Genentech, Astellas, Lilly) licensed it, and that Lilly is now buying the platform outright in bankruptcy, is the strongest possible third-party validation of the moat.

Where the "moat" failed: a moat that cannot be funded is not a moat. Sangamo had bargaining power over no one by 2025 — partners walked (Pfizer, earlier Novartis + Biogen), and the company was reduced to "early-stage discussions" for a Fabry commercialization deal it could not close. Bargaining power inverted entirely: in Chapter 11 the partners (Lilly, Astellas) set the price as acquirers, not licensees. The technology moat is real; the commercial and financial moat was always illusory for a sub-scale platform with no marketed product. Zinc-finger editing has also been competitively lapped by CRISPR/base/prime editing on mindshare and capital access (see Lens 7).

Lens 4 · Segments

Sangamo does not report business segments — it is a single R&D entity. The meaningful "segment" cut is revenue by partner and R&D spend by program. segments.csv on the shelf is empty; both tables below are research-layer-grounded from the 10-K MD&A.

Revenue by source (FY2025 vs FY2024):

• Total revenue $39.6M (2025) vs $57.8M (2024), −32%.
• The 2025 decline was driven by −$49.9M from the Genentech collaboration (a step-down), partially offset by +$18.4M Lilly capsid license, +$6.0M + $5.0M Pfizer items, +$1.4M Sigma, +$1.0M Astellas.
• Going forward management expected revenue to be "primarily from license agreements" — i.e. royalty crumbs, not a growth line.

R&D spend by program (FY2025 vs FY2024), $ thousands:

The trend is unmistakable: everything was being starved to feed the Fabry BLA, the one shot at a near-term approval that might attract a commercialization deal. That bet did not close in time.

---

Phase B — Measure performance (+clinical overlay: Pipeline-by-phase + Catalyst calendar substitute for Comps where noted)

Lens 5 · Pipeline by phase (clinical overlay — replaces standard "Earnings Result")

The asset table is the company. As of the 10-K and now the bankruptcy disclosures:

The brutal irony: Sangamo holds a Phase-3-successful hemophilia gene therapy (giroctocogene hit superiority over standard-of-care prophylaxis) and a registrational Fabry asset — and still went bankrupt, because (a) Pfizer judged the one-time-hemophilia-gene-therapy commercial opportunity uneconomic and walked, extinguishing ~$220M of anticipated milestones, and (b) no one would pay enough, fast enough, for Fabry. Positive data did not equal a viable business.

Latest financial print (Q1 2026, for completeness): revenue $1.4M (vs $6.4M Q1'25, −78%); total opex $33.4M; net loss $31.0M; EPS −$0.08; weighted shares 389.6M. Cash burn ran ahead of the cash balance — this quarter alone consumed roughly a full year's worth of the residual liquidity buffer.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the shelf (transcripts=0). Sentiment is reconstructed from filings + web. The arc over ~18 months is a textbook collapse of confidence:

• Mid-2024: optimism — Genentech (Aug 2024) and Astellas (Dec 2024) capsid deals signed; AFFINE Phase 3 win (Jul 2024); STAC-BBB framed as platform of the future.
• Dec 2024: regime change — Pfizer terminates hemophilia; management language pivots to "strategic alternatives," cost cuts, "reprioritized core neurology."
• FY2025 10-K (Mar 2026): the word "going concern" and "seek protection under the U.S. Bankruptcy Code in the very near term" appear in the forward-looking statements themselves — extraordinary placement; the auditor (EY, PCAOB ID 42) issued a going-concern emphasis paragraph.
• Q1 2026 10-Q (May 2026): Nasdaq delisting + OTCQB transition disclosed; "early-stage discussions" on Fabry partner with "no assurance".
• Jun 2026: Chapter 11; CEO Macrae frames it as "a clear framework to pursue value-maximizing transactions" — the language of an orderly wind-down, not a turnaround.

Phrases that disappeared: "growth," "commercial launch on our own," "pipeline expansion." Phrases that took over: "going concern," "very near term," "strategic alternatives," "value-maximizing." The tone went from building a company to salvaging asset value for creditors.

Lens 7 · Catalyst calendar + mechanism comps (clinical overlay — replaces P/E comps)

The only catalysts that now matter are bankruptcy-process events, not clinical readouts (the clinical value accrues to the acquirers):

Mechanism comps (the living gene-therapy/editing cohort, for context on what the market funds vs. abandons):

The comp set tells the story: the editing/gene-therapy field is bifurcated between a few well-capitalized leaders (>$1B cash) and a long tail of sub-scale platforms that the capital markets stopped funding. Sangamo — older zinc-finger lineage, no marketed product, ~$28M cash against ~$112M annual R&D — sat at the bottom of that tail and fell off. Note even Editas, with a worse clinical position (no clinical programs), carries 2× Sangamo's market cap purely because it has ~$220M cash and runway to 2027. Cash, not science, is the differentiator here.

Lens 8 · Stock-Price Catalysts (5-year, >5% moves)

Sangamo's chart is a 5-year, ~99% drawdown. The pattern is unambiguous: the stock trades on partner status, not clinical data. Every leg down is a partner leaving.

• Jun 2023: Novartis and Biogen both terminate neuro collaborations → revenue cliff from $176.2M (2023) → $57.8M (2024).
• Jul 2024: AFFINE Phase 3 success (positive clinical data) — notably did not durably re-rate the stock; the market had moved on from "data" to "who pays."
• Dec 2024: Pfizer terminates hemophilia for convenience → ~56–60% single-day collapse, extinguishing ~$220M anticipated milestones. This is the event that "effectively foreclosed equity financing."
• 2025: death-spiral financing — $52.2M ATM + a May 2025 warrant-laden raise at $0.50/unit; share count exploded from 212.8M (YE'24) → 350.7M (YE'25) → 414.3M (May 2026).
• Apr–May 2026: Nasdaq minimum-bid non-compliance → delist determination (28 Apr) → trading suspended, moved to OTCQB (5 May).
• Jun 2026: Chapter 11 (23 Jun); ticker → SGMOQ (24 Jun); ~$0.15.

What the market reacts to for this name: partner economics and survival, full stop. Positive Phase 3 data moved it less than a single partner's exit. That is the signature of a company the market correctly priced as balance-sheet-first, science-second.

---

Phase C — Judge people & books (+clinical: add Science & exclusivity)

Lens 9 · Management

CEO: Sandy Macrae, M.B., Ch.B., Ph.D. — since June 2016 (~10 years). Prior: Global Medical Officer, Takeda (2012–2016); SVP Emerging Markets R&D, GSK (2001–2012). A physician-executive, professional manager archetype (not a founder).

• Track record: Macrae's decade is, bluntly, a decade of value destruction — the stock is down ~99% over five years and the company is now bankrupt. To be fair, he steered Sangamo into the marquee partnerships (Pfizer 2017, Biogen 2018, Novartis, Genentech/Astellas/Lilly 2024) that funded it for years — but every major partner ultimately walked, and the company never advanced a single product to its own approval/launch on his watch.
• Skin in the game: insider ownership is immaterial relative to a 414M-share float diluted to oblivion (insider-transactions.csv not on shelf; not separately sourced — n/a). After the death-spiral raises, management's economic stake is negligible.
• Capital allocation: the defining failure. Years of >$100M annual R&D across a scattershot pipeline (hemophilia, Fabry, neuro, pain, Treg, France cell-therapy) with no prioritization until the cash was nearly gone; serial dilutive equity issuance at collapsing prices; and a fatal over-reliance on partner milestones to fund neurology — so when Pfizer's ~$220M evaporated, there was no plan B. ROE/ROIC are deeply negative throughout (accumulated deficit $1.66B at Q1'26).
• Red flags: the most damning is that the going-concern and bankruptcy warnings were telegraphed for two quarters before the filing — management saw the wall and could not avert it. Repricing warrants down to $0.47 to keep a single investor engaged (Feb 2026) is the act of a company with no leverage.
• Verdict: a credible scientist-administrator who was a competent deal-doer but a poor capital allocator and prioritizer, presiding over the destruction of a $1.6B+ cumulative investment. The bankruptcy is the indictment.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst — but note the headline risk is no longer hidden accounting; it is overt insolvency.

• Going concern / negative equity (the dominant flag): EY issued an explicit going-concern opinion; stockholders' deficit of −$19.0M at Q1'26 (−$14.3M at YE'25) — liabilities exceed assets.
• Cash vs. earnings divergence: FY2025 net loss −$122.9M; net cash used in operations −$97.2M; the gap is non-cash impairment ($13.2M) + SBC ($9.1M) + D&A ($4.0M). Burn is real cash, not accrual noise — the opposite of the usual "earnings flatter cash" concern; here cash is simply running out.
• Revenue recognition / deferred revenue: revenue is lumpy collaboration recognition (ASC 606); deferred revenue fell to $0.9M current (from $7.6M) as performance obligations ran off — i.e. the future revenue cupboard is bare.
• Impairments: $13.2M (2025, Brisbane ROU asset) + $5.5M (2024, France) — long-lived assets being written down as the footprint is abandoned. Management flags possible further impairments.
• Dilution / SBC: share count tripled in ~16 months (212.8M → 414.3M). SBC $9.1M (2025). This is shareholder value transfer via the printing press.
• NOLs: $980.4M federal + $470.3M state + $129.3M French NOL carryforwards — large but likely impaired/limited by §382 ownership-change rules on any sale, and worthless to wiped-out equity holders.

Regulatory findings (required sub-section):

• SEC Litigation Releases: None found for Sangamo in the EDGAR EFTS search period (since 2021-06-30).
• SEC AAERs: None found.
• Non-SEC enforcement (web): No material FTC/DOJ/FDA enforcement actions, consent decrees, or fines surfaced. The FDA interactions are ordinary BLA-review matters, not enforcement.
• Item 3 Legal Proceedings (10-K): No material litigation disclosed beyond ordinary course as of the FY2025 10-K. (Securities class-action risk is elevated post-bankruptcy given the 99% drawdown, but none confirmed as of this dossier.)
• Bankruptcy note: the Chapter 11 itself (Case 26-10989, D. Del.) is the dominant "legal" fact and is voluntary, not an enforcement action.
• Net: No material accounting-fraud or regulatory-enforcement findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-30. The failure is one of solvency and strategy, not malfeasance.

Lens (Science & exclusivity — clinical overlay add)

• Mechanism validation: STAC-BBB's NHP data (700× AAV9, broad CNS biodistribution, liver/DRG de-targeting) is genuinely differentiated and is why three large pharmas engaged and Lilly is buying it — strong third-party validation. Fabry (ST-920) showed a clean Accelerated-Approval path on eGFR slope; hemophilia (giroctocogene) hit Phase 3 superiority — the science worked.
• IP / exclusivity: capsid families run to 2040–2045; deep zinc-finger estate. This is the durable asset.
• The disconnect: validated science + long-dated IP + zero balance-sheet runway = the assets get sold for cents-on-the-dollar-of-prior-investment to the partners who can actually fund them. Exclusivity protected the technology; it did nothing to protect the equity holder.

---

Phase D — Project & stress-test (+clinical: rNPV / recovery analysis replaces EPS)

Lens 11 · Recovery analysis & runway-to-catalyst (clinical overlay — replaces forward EPS)

EPS projection is not meaningful — the company is being liquidated. The right Lens-11 question is recovery to the equity in a §363 sale. This is an `` waterfall using sourced inputs:

Estimated estate value (stalking-horse floor):

• Lilly package: $50M cash + assumed liabilities + contingent milestones/royalties
• Astellas / Fabry: $25M cash at close + up to $25M milestones
• Excluded assets (hemophilia giroctocogene, ST-503 pain, Treg) sold separately at auction — value uncertain, plausibly modest given Pfizer already deemed hemophilia uneconomic. n/a — not reliably sourced.
• Cash floor at close ≈ $75M, plus up to ~$25M+ contingent, plus any topping bids above stalking horses.

Claims ahead of equity (the waterfall):

1. DIP loan $30M at 12% (+2% default), super-priority, senior secured — paid first.
2. Total pre-petition liabilities ≈ $78.9M (Q1'26): A/P $19.3M, accrued comp $18.3M, other accrued $15.1M, lease liabilities ~$19.3M long-term, deferred revenue $6.3M, etc. — admin + priority + unsecured claims.
3. Equity — residual, last.

**** Roughly ~$75M cash floor − $30M DIP (+ accrued interest, professional fees) − ~$79M other liabilities ≈ deeply negative to equity before any topping bids or the excluded-asset proceeds. For the common to recover anything, the auction would need to clear materially above the ~$100M combined stalking-horse-plus-contingent figure and the excluded assets to fetch real money — possible but not the base case. Base case: equity recovery ≈ $0. The ~$62M market cap at ~$0.15 is the market pricing a lottery ticket on a topping-bid windfall + NOL/contingent optionality, not residual value.

Brier forecast (binary, for tracking): "SGMO/SGMOQ common-equity holders receive a recovery > $0.00/share through the Chapter 11 plan" — p ≈ 0.10, resolves at plan confirmation/sale close (est. by 2026-12-30 DIP maturity). (Per --watchlist rules, the forecast.ts create step is skipped in the unattended loop; logged here as the scoreable claim for a later manual entry.)

Lens 12 · Bull vs Bear

Bull case (the equity-stub lottery, not a going-concern bull): The science is real and validated — STAC-BBB drew three pharma partners and a Lilly buyout; ST-920 Fabry has a clean Accelerated-Approval path; giroctocogene is Phase-3-positive. In a §363 auction, competing strategic or PE bidders could top the stalking horses, and the excluded hemophilia/pain assets could fetch unexpected value, pushing recovery toward equity. The huge NOLs ($980M federal) are theoretically valuable to an acquirer. If everything breaks right, the stub could multiply off $0.15.

Bear case (the base case — 2–3 permanent impairers):

1. The capital structure is the impairment — $30M super-priority DIP + $79M liabilities sit ahead of equity; the stalking-horse floor ($75M cash) doesn't clear them. Equity is structurally subordinated to a near-zero.
2. The best assets are already spoken for at a floor set by the only logical buyers. Lilly/Astellas hold information and bargaining advantages (they were the licensees); a robust topping war is unlikely for niche gene-therapy assets one bidder already declined to fund (Pfizer/hemophilia).
3. Time decay — the DIP matures 30 Dec 2026; professional fees and accruing 12% interest erode any residual daily.

Pre-mortem (it's 18 months out and the long thesis broke): the auction cleared at-or-near the stalking-horse floor, the excluded assets sold for scraps, DIP + admin + unsecured claims absorbed the proceeds, the plan wiped out the common, SGMOQ was cancelled, and any "deep-value" buyer of the stub lost ~100%. This is the modal path.

Are multiples too high? There is no earnings multiple. The ~$62M equity market cap is too high relative to a base-case ~$0 recovery — it embeds optionality the waterfall doesn't support.

Contrarian view (what the market refuses to see): Bulls anchoring on "the science is great / Lilly is buying / it's too cheap at $0.15" are making a going-concern argument about a liquidation. The science being valuable is precisely why it gets sold to someone else — value flows to Lilly/Astellas/creditors, not to the pre-petition common. The market is also under-pricing securities-litigation and the certainty of cancellation at plan confirmation. The genuinely contrarian (and correct) read is the boring one: this is a zero, and the OTCQB bid is noise.

Lens 13 · Devil's Advocate (short-seller)

Dismantling even the lottery-ticket long.

• What structurally breaks the model: it already broke — there is no model, only an estate. Revenue is contractual collaboration crumbs ($1.4M in Q1'26) running to zero; there is no internal cash generation, ever, at the SGMO entity.
• Revenue concentration: ~100% partner-dependent; the partners became acquirers. Concentration risk fully realized.
• Why the moat is weaker than bulls think: a moat sold in bankruptcy to your former licensee is, by definition, a moat that did not protect you. Zinc-finger editing has been competitively eclipsed by CRISPR/base/prime editing for capital and mindshare (CRSP/NTLA each hold >$1B cash; SGMO held $28M).
• Most dangerous "competitor" bulls underestimate: the capital markets themselves — they simply stopped funding sub-scale gene therapy, and no science quality reopens that door once a going-concern doubt is public.
• Worst capital-allocation moves: funding a sprawling multi-indication pipeline on partner milestones with no buffer; serial dilution from 212M → 414M shares; warrant repricing to $0.47. Management optionality was preserved; shareholder value was not.
• What must hold for $0.15 to be "cheap": a competitive topping auction and meaningful excluded-asset proceeds and an unusually creditor-friendly waterfall and surviving litigation — a stack of low-probability conjunctions.
• Valuation if "growth" disappoints 20–30%: irrelevant framing — the relevant sensitivity is recovery if the auction clears at the floor: ~$0.
• Single scenario that permanently impairs: it has occurred (Chapter 11, 23 Jun 2026). The short/avoid thesis is already largely realized; the remaining trade is fading OTCQB pops into plan confirmation.

Lens 14 · Management Questions (ordered by information value)

Directed to the CEO / CRO / debtor's counsel in the Chapter 11 context:

1. What is the floor and expected range of total estate proceeds, and at what proceeds level (if any) does the common equity receive a recovery? (The only question that matters to a shareholder.)
2. Are there qualified competing bidders beyond Lilly and Astellas for any asset package, and what is the topping-bid threshold and auction date?
3. What is the expected recovery waterfall — DIP, admin/professional fees, priority, unsecured trade claims, then equity — in dollars?
4. What proceeds do the excluded assets (giroctocogene hemophilia, ST-503 pain, Treg) realistically fetch, given Pfizer already declined to commercialize hemophilia?
5. Will the $980M federal NOLs survive a §382 ownership change and do they add to any bid?
6. What are the break-up fees / expense reimbursements owed to the stalking horses, and how do they reduce net estate value?
7. Is the DIP sufficient to fund the case through close, or is a further draw/extension or conversion to Chapter 7 a risk before 30 Dec 2026?
8. What is the status and timing of the ST-920 Fabry BLA — does completion/acceptance increase the Astellas milestone consideration?
9. Are there pending or threatened securities class actions tied to the going-concern/partner disclosures?
10. What cure costs and contract-assumption liabilities attach to the assigned Lilly/Astellas agreements?
11. How are employee/retention (KEIP/KERP) and severance claims being treated relative to other creditors?
12. What are the lease-rejection economics (Richmond, Brisbane) and the resulting unsecured claims?
13. Did the board run a pre-petition marketing process, and how many parties engaged before the stalking horses were chosen?
14. What is the disposition of the non-therapeutic royalty streams (Sigma/Ligand) — are they a separate saleable asset?
15. Looking back, at what point did the board conclude a sale/bankruptcy was unavoidable, and would earlier prioritization or a partner deal in 2024 have changed the outcome?

---